Stockwinners Market Radar for April 26, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:25 EDT FICO CEO: We're very happy with the business - In an interview on CNBC's Mad Money, Will Lansing said there is a little overhang in the stock price from interest rates not coming down as fast as anticipated. FICO is competitive because it's good, not due to any special privileges, he noted. He feels the recent stock dip is a great buying opportunity and said the company is fairly valued.

17:57 EDT Southwest extends flight schedule through March 5, 2025 - Southwest Airlines Co. has extended its flight schedule through March 5, 2025, to allow customers to plan and book travel well into the new year. "We're positioning ourselves as a competitive choice in longer-term travel planning by displaying a greater depth of our schedule alongside our unique flexibility," said Ryan Green, Executive Vice President & Chief Commercial Officer. "I want to thank

17:39 EDT Faraday Future announces Nasdaq delisting determination - Faraday Future Intelligent Electric announced that it received a letter from The Nasdaq Stock Market LLC dated April 24, 2024, indicating that the company was not in compliance with Nasdaq Listing Rule 5810(c)(3)(A)(iii), as the company's securities had a closing bid price of $0.10 or less for ten consecutive trading days. The letter indicated that, as a result, the Nasdaq staff has determined to delist the company's securities from The Nasdaq Capital Market. As previously reported, on December 28, 2023, Nasdaq notified the company that the bid price of its listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days and, as a result, did not comply with Listing Rule 5550(a)(2). The company was provided 180 calendar days, or until June 25, 2024, to regain compliance with this rule.

16:51 EDT Society Pass annoucnes 1-for-15 reverse stock split - Society Pass announced that the board approved a proposed 1-for-15 shares reverse split of its common stock. Beginning with the opening of trading on May 1, the company's common stock will begin trading on a post-Reverse Split basis on the Nasdaq Capital Market under the same symbol "SOPA", but under a new CUSIP number of 83370P201. The objective of the Reverse Split is to enable the company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market.

16:40 EDT Clever Leaves trading resumes

16:32 EDT A2Z Smart Technologies receives Nasdaq notice letters - A2Z Smart Technologies announced that the company received notices from the Nasdaq Stock Market LLC on April 24, 2024, notifying the company that it is not in compliance with Nasdaq's minimum bid price requirement and minimum market value of listed securities requirement. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the company has a compliance period of 180 calendar days, or until October 21, 2024, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the company's common shares is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the company with a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance by October 21, 2024, the company may be eligible for an additional 180 calendar day grace period if it meets certain requirements.

16:23 EDT Bridgewater Bancshares names Mary Jayne Crocker CSO, Laura Espeseth CAO - Bridgewater announced additional strategic role transitions to fortify its leadership structure: Mary Jayne Crocker has been appointed to the role of executive VP and chief strategy officer, or CSO, previously serving as executive VP and COO. In this capacity, Crocker will drive the shaping of long-term strategic plans and ensure alignment with Bridgewater's objectives. Laura Espeseth, previously senior VP, steps into the role of chief accounting officer, or CAO, where she will be responsible for all accounting operations, ensuring the integrity of financial reporting, and compliance with regulatory requirements. In this capacity, Espeseth will play a key role in shaping Bridgewater's financial strategy and ensuring its long-term financial health.

16:11 EDT Zhihu plans to implement ADS ratio change - Zhihu announced that it plans to change the ratio of its American depositary shares to its Class A ordinary shares, par value $0.0001 per share, from the current ratio of two ADSs representing one Class A ordinary share to a new ratio of one ADS representing three Class A ordinary shares, effective on or about May 10, U.S. Eastern Time. For the company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-six reverse ADS split. Upon the Effective Date, ADS holders will be required to surrender and exchange every six existing ADSs then held for one new ADS. JPMorgan Chase Bank, N.A., as the depositary bank for the company's ADS program, will arrange for the exchange. The company's ADSs will continue to be traded on the New York Stock Exchange under the ticker symbol "ZH."

16:10 EDT Cytokinetics names Sung Lee as CFO - In a regulatory filing, Cytokinetics disclosed that on April 23, the company entered into an employment offer letter with Sung Lee, pursuant to which Lee has agreed to serve as the company's Executive Vice President, CFO, effective as of May 8. On the start date, Lee will assume the duties and responsibilities of the company's principal financial officer from Robert Blum, the company's President and CEO, who has been serving as the company's principal financial officer on an interim basis

16:06 EDT Clever Leaves trading halted, news pending

16:03 EDT Diamondback Energy shareholders approve merger with Endeavor Energy Resources - Diamondback Energy announced that its stockholders have approved the issuance of shares of Diamondback common stock in connection with the proposed business combination with Endeavor Energy Resources, L.P. Additionally, Diamondback stockholders approved a proposal to amend the company's certificate of incorporation to increase the authorized number of shares of Diamondback common stock. The business combination with Endeavor is subject to customary closing conditions, including termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

14:40 EDT HHS says proposed menthol cigarette rule to take 'significantly more time' - U.S. Department of Health and Human Services Secretary Xavier Becerra issued the following statement on the proposed menthol cigarette rule: "This rule has garnered historic attention and the public comment period has yielded an immense amount of feedback, including from various elements of the civil rights and criminal justice movement. It's clear that there are still more conversations to have, and that will take significantly more time." Publicly traded companies in the tobacco products space include Altria Group (MO), British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM). Reference Link

14:16 EDT Rivian to open its DC fast charging network to all compatible vehicles in 2024 - Rivian revealed "the latest evolution of its Rivian Adventure Network DC fast charging network," including a new charger that can accommodate a wider range of electric vehicles, or EVs. "After nearly two years of growth and reliably serving Rivian drivers as they embark on long-distance adventures, Rivian plans to begin opening its fast-charging network to other EVs later this year," the company stated. Reference Link

13:01 EDT Baker Hughes reports U.S. rig count down 6 to 613 rigs

12:03 EDT Ball Corp. says 'very comfortable' buying back stock at this level - Comments taken from Q1 earnings conference call.

12:00 EDT Tutor Perini rises 20.5% - Tutor Perini is up 20.5%, or $2.85 to $16.74.

12:00 EDT Oil States falls -15.5% - Oil States is down -15.5%, or -82c to $4.50.

12:00 EDT Boyd Gaming falls -16.1% - Boyd Gaming is down -16.1%, or -$10.15 to $52.74.

11:45 EDT Alphabet announcing $3B in investments in data centers in Virginia and Indiana - Ruth Porat, President & Chief Investment Officer; Chief Financial Officer, Alphabet & Google, said in a blog post: "Google is announcing $3 billion in investments to build or expand our data center campuses in Virginia and Indiana. Virginia: We're investing an additional $1 billion, with plans to expand our three existing Virginia data center campuses - bringing our total investment to date in the state to more than $4 billion. Indiana: In the Midwest, we announced a $2 billion investment in our newest data center campus in Fort Wayne, Indiana." Google is also announcing a $75M Google AI Opportunity Fund, made possible with support from Google.org, its philanthropic arm, Porat said. "Through this fund, Google.org will work with nonprofit, education, and other sectors to train one million Americans of all backgrounds and provide them with AI skills at no cost. Alongside the fund, today we are launching the Google AI Essentials course, built by Grow with Google and AI experts from Google's Research, Technology & Society team and across the company. The course will help teach foundational skills to workers and allow participants to gain essential AI skills to apply in their daily life," the blog post stated. Reference Link

11:31 EDT Kellanova announces plans to increase dividend to 57c in Q3 - Kellanova announced that its Board of Directors declared a dividend of 56c per share on the common stock of Kellanova, payable on June 14, 2024, to shareowners of record at the close of business on June 3, 2024. In addition, the Kellanova Board of Directors announced plans to increase the quarterly dividend to 57c per share beginning with the third quarter of 2024.

10:22 EDT IBM signs agreements with government of Canada, Quebec valued at C$187M - IBM, the Government of Canada, and the Government of Quebec announced agreements that will strengthen Canada's semiconductor industry, and further develop the assembly, testing and packaging capabilities for semiconductor modules to be used across a wide range of applications including telecommunications, high performance computing, automotive, aerospace & defense, computer networks, and generative AI, at IBM Canada's plant in Bromont, Quebec. The agreements reflect a combined investment valued at approximately C$187M. In addition to the advancement of packaging capabilities, IBM will be conducting R&D to develop methods for scalable manufacturing and other advanced assembly processes to support the packaging of different chip technologies, to further Canada's role in the North American semiconductor supply chain and expand and anchor Canada's capabilities in advanced packaging.

10:16 EDT BLET endorses Ancora's slate of directors for Norfolk Southern - The Brotherhood of Locomotive Engineers and Trainmen, an affiliate of the Rail Division of the International Brotherhood of Teamsters, announced that it has determined, after careful review and new developments since the proxy battle began, that a change in leadership at Norfolk Southern Corporation is necessary and in the best interest of both BLET members and the railroad's long-term success. "BLET's three elected General Chairmen representing locomotive engineers and trainmen at Norfolk Southern met with Ancora's leadership team yesterday and determined that they are the right leaders for Norfolk Southern moving forward," said BLET National President Edward Hall. "After the railroad's CEO Alan Shaw hired COO John Orr and following the public comments of both those executives on their strategy for NS, our General Chairmen determined that a change at the top is needed. Although this decision was not easy, the General Chairmen believe it is necessary."

10:08 EDT Barfresh Food Group announces wins within the education channel - Barfresh Food Group has continued to expand its presence within the education channel and announced a number of recent large wins within the education channel. The Company recently secured seven school co-operatives, serving over 2,200 school locations and approximately 1.5 million students. These new school locations will serve a variety of the Company's products, including its carton and bottle smoothie products, 5:1 100% juice concentrates and 1:1 bulk easy pour smoothie concentrates.

10:04 EDT Skillsoft trading halted, volatility trading pause

10:01 EDT Boyd Gaming falls -12.8% - Boyd Gaming is down -12.8%, or -$8.06 to $54.83.

10:00 EDT U.S. Silica rises 19.5% - U.S. Silica is up 19.5%, or $2.55 to $15.61.

10:00 EDT AbbVie says Humira downdraft 'within what was assumed'

09:51 EDT Avenue Therapeutics trading resumes

09:48 EDT U.S. Silica rises 19.3% - U.S. Silica is up 19.3%, or $2.52 to $15.58.

09:47 EDT Aon plc falls -12.4% - Aon plc is down -12.4%, or -$37.94 to $268.06.

09:47 EDT Kinsale Capital falls -17.0% - Kinsale Capital is down -17.0%, or -$77.09 to $376.00.

09:41 EDT Atomera trading resumes

09:39 EDT DESTINY TECH100 INC trading resumes

09:37 EDT Newell Brands trading resumes

09:36 EDT Atomera trading halted, volatility trading pause

09:33 EDT DESTINY TECH100 INC trading halted, volatility trading pause

09:32 EDT IMAC Holdings Inc trading halted, volatility trading pause

09:26 EDT Tevogen CEO highlights expected reporting of $94.9M liability elimination - CEO Ryan Saadi said, "In anticipation of the filing of our annual financial statements, I would like to provide our investors with a few reflections on anticipated financial results. First, we expect to report that as of December 31, 2023, and for year-end 2023, the liabilities and net losses of Tevogen Bio Inc were primarily related to convertible promissory notes. Those notes were assumed and converted into shares of Tevogen Bio Holdings Inc in connection with the business combination between Tevogen Bio Inc and Semper Paratus Acquisition Corporation that closed on February 14, 2024. We expect to report that the net losses of Tevogen Bio Inc consisted primarily of non-cash charges related to the change in the fair value of the convertible promissory notes, not the operating expenses of Tevogen Bio Inc, and that Tevogen Bio Inc's operating expenses for 2023 were $8.8 million. Due to the conversion of the convertible promissory notes, we will report that on a pro forma basis, there are no longer any liabilities associated with convertible promissory notes, and that the non-cash charge related to the change in the fair value of the notes has been eliminated from the pro forma condensed combined statement of operations. We anticipate disclosing that of the $94.9 million of balance sheet liabilities that were removed by the conversion of the notes, $80.7 million were current liabilities and $14.2 million were long-term liabilities. Second, I'd like to reflect on our recent leadership appointments and the newly launched initiative in Artificial Intelligence. The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access. Mittul Mehta, our Chief Information Officer and Head of Tevogen.ai, brings over 20 years of experience in information technology and nearly a decade in senior management roles. Previously, Mr. Mehta served as Senior Vice President, Global Head of Platforms Security, Mobility & Cloud Security at Jefferies LLC, where he played a key role in enterprise strategy. His extensive experience across various organizations, including Avanade Inc., Macy's Inc., MetLife Inc., and Microsoft Corporation, demonstrates his ability to align technology with business objectives and lead teams effectively through complex projects and shifting priorities. Looking ahead, Mr. Mehta will share his vision for AI in biotechnology and healthcare through featured speeches including at the Longwood Healthcare Leaders Spring MIT conference and Hogan Lovells Annual Health Care AI Law and Policy Summit. Tevogen also appointed Tapan V. Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio. Most recently, Mr. Shah was Director, Relationship Management, in Citigroup's Client organization, where he was also a member of the Executive Office. Prior to Citigroup, he worked in Morgan Stanley's asset management business focused on Equity Strategy and Product Development. Mr. Shah started his career in the Investment Banking Division of Goldman Sachs. In this new position, Mr. Shah will lead communications with all financial stakeholders, including shareholders, research analysts, and investment bankers. He will also lead the M&A and capital raising functions at Tevogen Bio. We believe our allogeneic, precision T cell technology platform, ExacTcell, represents a significant scientific breakthrough that has the potential to develop a new class of off the shelf T cell therapeutics with diverse applications spanning virology, oncology, and neurology."

09:17 EDT Solowin Holdings bolsters partnership with OSL Digital - SOLOWIN HOLDINGS announced that the Company, through its subsidiary, Solomon JFZ strengthened the partnership with OSL Digital Securities to facilitate the in-kind subscription and redemption processes essential for the successful deployment and management of Hong Kong's first spot virtual asset exchange-traded funds. Solomon is the first batch of SFC-approved participating dealer of this innovative in-kind subscription and redemption for spot virtual asset ETFs in Hong Kong. As a participating dealer, Solomon will facilitate the in-kind transactions, enabling investors to subscribe to or redeem ETF shares directly with the underlying digital assets, thereby significantly enhancing both the liquidity and accessibility of digital asset investments.

09:15 EDT Mitesco appoints two members to advisory board - Mitesco has added two additional professionals to its recently formed "Advisory Board". The latest appointments to the Advisory Board who provide infrastructure, GIS, outsourcing and data center operations experience are as follows: Tom Simon is the owner of Synthos, a provider of development and support services specializing in geographical information systems based in Seattle, Washington. Chris McLoughlin has spent his career in software and systems development and is an owner of Accucom Consulting, Inc

09:06 EDT Safe and Green Development executes contract to sell Lago Vista site - Safe and Green Development announced the Company received and executed a commercial contract to sell the Company's Lago Vista site to an unnamed buyer. The Lago Vista property is an approximately 60-acre waterfront property located on Lake Travis, Texas. After evaluating the current timeline of the joint offer and the purchase offer, the Company decided to sell the property to strategically reinforce its balance sheet. The closing of this transaction would result in approximately $5,000,000 of debt to be extinguished from the Company's balance sheet and yield additional non-dilutive cash proceeds. The Lago Vista property was originally purchased by SG Devco's subsidiary for $3.5 million in 2021. Pursuant to the terms of the contract, the sale transaction is expected to close after a 70-day due diligence period and a subsequent 30-day closing period.

09:04 EDT American Rebel appoints Mihalek as CEO of Champion Safe - American Rebel Holdings announces the appointment of Thomas Mihalek as CEO of Champion Safe. Mihale has been under contract as a strategic consultant to Champion Safe for the past few months to learn, assess and provide recommendations for operational improvements at Champion Safe. Mihalek, as CEO of Champion Safe, will report directly to Corey Lambrecht, Chief Operating Officer of American Rebel Holdings.

09:03 EDT Safe Bulkers enters agreement for acquisition of one Japanese Kamsarmax - Safe Bulkers announced that it has entered into an agreement for the acquisition of a Japanese, 82,000 dwt, dry-bulk, Kamsarmax class vessel, with a scheduled delivery date within the fourth quarter of 2026. The newbuild vessel is designed to meet the Phase 3 requirements of Energy Efficiency Design Index related to the reduction of greenhouse gas emissions as adopted by the International Maritime Organization, and also comply with the latest NOx emissions regulation, NOx-Tier III. This newbuild vessel is a sister vessel to a number of newbuilds in our orderbook with advanced energy efficiency characteristics resulting to lower fuel consumption. Dr. Loukas Barmparis, President of the Company commented: "This latest newbuild order with relatively prompt delivery compared to present slot availability, is part of our fleet renewal strategy and reflects our plans to own one of the most environmentally efficient dry bulk fleets in the market."

09:02 EDT Takeda announces CHMP opinion recommending approval of fruquintinib - Takeda announced that the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors, or VEGFR, -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer, or mCRC. The European Commission, or EC, will consider the CHMP opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union, Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.

08:56 EDT Carbon Streaming provides update on Rimba Raya Project - Carbon Streaming provides an update on the Rimba Raya Project. The Company has learned of two third-party media reports that claim PT Rimba Raya Conservation, the local concession holder at the Project, has had its Forest Utilization Business License revoked by the Indonesian Government's Ministry of Environment & Forestry. Carbon Streaming is actively working with InfiniteEARTH Limited and Infinite-Earth Nusantara, the Company's Rimba Raya project proponent and owner of the carbon rights, and local Indonesian counsel to validate the claims made by the third-party media reports. To the best knowledge of the Company, the Concession License is held by PT Rimba Raya Conservation having been recently renewed in November 2021. Carbon Streaming is advised by InfiniteEARTH that it intends to dispute any revocation of the Concession License that would impact its carbon rights and is seeking clarification from the MOEF as to the current status of the Concession License and the ramifications of any such revocation, including on the status of InfiniteEARTH as the project proponent of Rimba Raya under the Indonesian government's national carbon registry, Sistem Registri Nasional Pengendalian Perubahan Iklim, and any impact on their rights to both historical and future credits as established through the collaboration agreement with PT Rimba Raya Conservation. To the knowledge of InfiniteEARTH, the status of InfiniteEARTH as project proponent of the Project has not changed, nor has the validation of the Project that InfiniteEARTH conducted with the SRN Registry been reversed. While unable to provide assurance regarding InfiniteEARTH's status on the SRN Registry, the status of the validation of the Project with the SRN Registry, or the status of the Concession License, Carbon Streaming will continue to work closely with InfiniteEARTH on its active engagement with its local partners, the MOEF and the Indonesian Government to preserve the continuity of the Project. The Company entered into a purchase and sale agreement dated July 30, 2021 with InfiniteEARTH in respect of the Rimba Raya project. The Company will continue to update shareholders in respect of further developments in respect of the Rimba Raya project and the Rimba Raya Stream.

08:39 EDT Exagen to reduce size of board to seven from nine - Exagen announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. He was most recently with LunaPBC as the Chief Information and Privacy Officer. Additionally, in an ever-continuing effort to streamline operations at the company, Exagen announced that it is reducing the size of the Board of Directors from nine to seven, a change that has been carefully planned and complements the long-term strategy. Brian Birk, Ebetuel Pallares, Ph.D. and Wendy Johnson have all agreed to step down from the Board of Directors, effective on the date of the annual shareholder meeting on June 10th, 2024.

08:36 EDT Bannix Acquisition receives NASDAQ notification of non-compliance - Bannix Acquisition announced that on April 25, 2024, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market advising the Company that the Company did not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ had not received the Company's Annual Report on Form 10-K for the year ended December 31, 2023. NASDAQ informed the Company that it has 60 days from the date of the letter to submit a plan to regain compliance with respect to this delinquent report. If NASDAQ approves the Company's plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-K, or until February 12, 2024, to regain compliance.

08:36 EDT Align Technology announces $150M share repurchase program - Align Technology announced that it is planning to repurchase $150M of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023.

08:33 EDT Biodexa Pharmaceuticals enters into exclusive license to eRapa - Biodexa Pharmaceuticals announced it entered into a definitive agreement with Rapamycin Holdings for the rights to eRapa under an exclusive, worldwide license to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa. Stephen Stamp, CEO and CFO of Biodexa said, "Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa's oncology pipeline and adds numerous valuation catalysts for our stakeholders. We are delighted to be working with the Emtora team which has excelled in bringing eRapa close to the end of Phase 2 in Non-muscle Invasive Bladder Cancer and to the beginning of a Phase 3 trial in FAP, a devastating disease for which there is currently no approved pharmacological agent for altering its progression. Left untreated, it almost always leads to incredibly invasive surgery and a major deterioration in the quality of life."

08:32 EDT Allogene awarded $15M grant from CIRM to support ALLO-316 development - Allogene Therapeutics announced that it has received a $15 million grant from the California Institute for Regenerative Medicine, CIRM, to support the clinical development of ALLO-316, an AlloCAR T investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma, RCC. The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.

08:25 EDT Gilead announces FDA approval for updated Biktarvy label - Gilead announced the FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy to treat pregnant people with HIV-1, or PWH, with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of Biktarvy in pregnant PWH who have suppressed viral loads and no known resistance to any components of Biktarvy in their second and third trimesters and through a median of 16 weeks postpartum. This update makes Biktarvy the only second-generation integrase strand transfer inhibitor-based single-tablet regimen with in-label clinical trial data and FDA approval in virologically suppressed adults who are pregnant. The U.S. Department of Health and Human Services perinatal guidelines recognize Biktarvy as having sufficient data to support being recommended as an alternative complete regimen for use in pregnancy and for people who are trying to conceive. Additionally, guidelines recommend continuing Biktarvy for PWH already on treatment who are virologically suppressed and tolerating treatment well who may become pregnant.

08:06 EDT Smart for Life announces availability of white paper on Nutraceuticals industry - Smart for Life announced the release of a white paper on the Nutraceuticals industry. Entitled "Sector Opportunity: Nutraceutical Industry Growth Due to Demand for Preventative Health Products," the white paper describes how the nutraceutical industry has been growing at a robust rate thanks to an expanding interest in self-care as healthcare costs have risen. From the white paper, "The pandemic has also spurred sales of dietary supplements such as multivitamins. Globally, the preventive healthcare technologies and services market is estimated to reach $432.4 billion by the end of 2024, according to a Grand View Research, Inc. report. The firm found that the key factors driving the market expansion include the growing awareness of self-care measures, which, in turn, helps to boost nutraceutical sales." The paper goes on to say, "The United States continued its leadership in the nutraceuticals industry, with a 23.4% global market share, underpinned by its robust research and development capabilities, according to Future Market Insights. The company forecasts that the global nutraceuticals market will likely climb from $418 billion in revenues in 2023 to $703 billion by 2033."

08:04 EDT Genius Group announces new shareholders - Genius welcomed leading education entrepreneurs as new shareholders of the Company. Genius Group's new investors include: Brent Richardson, Past CEO and Chairman of Grand Canyon Education. Mr Richardson led the transformation of Grand Canyon University from a near-bankrupt institution in 2004 to an early pioneer in online education and a global institution with over 100,000 students worldwide. Dr Ali Saeed Bin Harmal Aldhaheri, Founder and Chairman of Abu Dhabi University. Dr Ali has built Abu Dhabi University into one of UAE's leading academic insititutions. He is also the First Vice Chairman of the Abu Dhabi Chamber of Commerce Board of Directors and a member of the Economic Cooperation Committee for Government and Private Sectors in Abu Dhabi. Michael Moe, Founder and CEO of GSV Ventures. Mr Moe is an early investor in Edtech companies including Coursera, Chegg, Course Hero, Masterclass, and private investor in companies such as Meta, Twitter, Spotify, Coursera and Palantir. In addition to being a new shareholder in Genius Group, Mr Moe will also be joining the Genius Group board as Non Executive Chairman. Mr Richardson, Dr Ali and Mr Moe, together with various other investors, are joining Genius Group as new shareholders following the completion of the previously announced Genius Group and FatBrain AI transaction.

08:02 EDT iClick Interactive Asia announces termination of merger agreement - iClick Interactive Asia Group announced the termination of the previously announced agreement and plan of merger, dated as of November 24, 2023, by and among the company, TSH Investment Holding Limited, and TSH Merger Sub Limited. On March 29, 2024, the company delivered to the Parent a notice confirming the satisfaction of the closing conditions under the Merger Agreement and that the company is ready, willing and able to consummate the closing contemplated under the Merger Agreement. Since the delivery of the Closing Notice, the company has been communicating and cooperating with the Parent, Merger Sub and their representatives towards the Closing, but the Parent and Merger Sub have failed to complete the Closing within ten Business Days following the delivery date of the Closing Notice pursuant to Section 8.03(b) of the Merger Agreement. On April 26, 2024, the company sent a notice of termination to the Parent and the Merger Sub pursuant to Section 8.03(b) of the Merger Agreement, notifying the Parent and the Merger Sub that the company is exercising its right to terminate the Merger Agreement pursuant to Section 8.03(b) of the Merger Agreement and demanding the Parent to pay the $1.8M termination fee pursuant to Section 8.06(b) of the Merger Agreement by May 9, 2024. As a result of the termination of the Merger Agreement, the proposed merger will not be completed.

07:54 EDT U.S. Silica jumps 19% to $15.52 after buyout offer from Apollo Global funds

07:42 EDT AbbVie reports Q1 global revenue from immunology portfolio $5.371B, down 3.9% - Global net revenues from the immunology portfolio were $5.371B, a decrease of 3.9 percent on a reported basis, or 3.1 percent on an operational basis, due to Humira biosimilar competition. Global Humira net revenues of $2.270 billion decreased 35.9 percent on a reported basis, or 35.2 percent on an operational basis. U.S. Humira net revenues were $1.771 billion, a decrease of 39.9 percent. Internationally, Humira net revenues were $499 million, a decrease of 15.8 percent on a reported basis, or 11.6 percent on an operational basis. Global Skyrizi net revenues were $2.008 billion, an increase of 47.6 percent on a reported basis, or 48.0 percent on an operational basis. Global Rinvoq net revenues were $1.093 billion, an increase of 59.3 percent on a reported basis, or 61.9 percent on an operational basis.

07:37 EDT Vision Marine announces resignation of board member Patrick Bobby - The Company announces the resignation of Mr. Patrick Bobby as a member of its Board of Directors and as its Head of Performance & Special Projects, effective April 22, 2024. Mr. Bobby, who co-founded the Company and has served on its board as well as in several senior management positions since the Company's inception, has decided to pursue other projects.

07:35 EDT Vision Marine files patent for advanced system communication encryption - Vision Marine Technologies announced the patent filing for its Communication Cryptographic System technology, integral to the E-Motion Electric Powertrain components on April 24, 2024. Enabled by high-capacity batteries, this key technology seeks to enhance security for users, ensure the conformity of all system components, and deliver an elevated boating experience. The E-Motion Powertrain's unique design features components that operate as a decentralized network, each performing its functions while interacting intelligently with others. The encrypted communication protocol is designed to ensure that these interactions remain secure and impenetrable to external interference, using a customized level of Advanced Encryption Standard. The aim of this unique feature is to enhance security for the user improving the conformity of all system components, mitigating risks of malfunctions.

07:23 EDT XP Inc. appoints Victor Mansur as CFO - XP Inc. announced that Victor Mansur has been appointed CFO effective August 1, succeeding Bruno Constantino. Constantino will work closely with Mansur to ensure a transition. Constantino will also continue to support XP in an advisory role for a 12-month period after the transition and will remain a member of XP's board of directors. In addition, current head of investor relations Andre Parize, who has been named chief investor relations officer, effective August 1 will report to Mansur. Mansur currently serves as XP's deputy CFO and has held a variety of senior roles at XP since joining the company in 2012.

07:17 EDT Apellis announces pegcetacoplan MAA review has been reset to Day 180 - Apellis Pharmaceuticals announced that the European Medicines Agency has reset the review of the marketing authorization application for intravitreal pegcetacoplan for geographic atrophy to the last phase of the initial assessment. The procedure is expected to be led by the original rapporteurs, and EMA has stated their intent to convene a new expert group meeting. Apellis anticipates an opinion from the Committee for Medicinal Products for Human Use no later than July 2024. The update follows the judgment by the Court of Justice of the European Union on March 14, 2024, which ruled on the organization of EMA's expert groups. The judgment has implications on EMA's policy for handling competing interests of experts. This decision by EMA is strictly procedural in response to the CJEU judgment and is not related to the pegcetacoplan data package. Apellis will continue to work closely with EMA on the review of the pegcetacoplan marketing application.

07:10 EDT Newell Brands provides update on organizational realignment - The company said, "In January 2024, the company announced an organizational realignment, which is expected to strengthen the company's front-end commercial capabilities, such as consumer understanding and brand communication, in support of the Where to Play / How to Win choices the company unveiled in June of 2023 (the "Realignment Plan"). In addition to improving accountability, the Realignment Plan should further unlock operational efficiencies and cost savings, reduce complexity and free up funds for reinvestment. As part of the organizational realignment, the company made several organizational design changes, which entailed: standing up a cross-functional brand management organization, realigning business unit finance to fully support the new global brand management model, further simplifying and standardizing regional go-to-market organizations, and centralizing domestic retail sales teams, the digital technology team, business-aligned accounting personnel, the Manufacturing Quality team, and the Human Resources functions into the appropriate center-led teams to drive standardization, efficiency and scale with a One Newell approach. The company will also further optimize Newell's real estate footprint and pursue other cost reduction initiatives. These actions are expected to be substantially implemented by the end of 2024. Once the organizational design changes are fully executed, the company expects to realize annualized pretax savings in the range of $65 million to $90 million, net of reinvestment, with $55 million to $70 million expected in 2024. Restructuring and related charges associated with these actions are estimated to be in the range of $75 million to $90 million and are expected to be substantially incurred by the end of 2024. During the first quarter 2024, the company incurred restructuring and related charges of $22 million related to the Realignment Plan."

07:07 EDT U.S. Silica to be acquired by Apollo Global funds for $1.85B in cash - U.S. Silica Holdings (SLCA) announced that it has entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo (APO) in an all-cash transaction that values the company at an enterprise value of approximately $1.85B. Under the terms of the agreement, U.S. Silica stockholders will receive $15.50 per share in cash for each share of common stock owned as of the closing of the transaction. The per share purchase price of $15.50 represents a 18.7% premium to U.S. Silica's closing share price of $13.06 on April 25, 2024, the last full trading day prior to the transaction announcement, and a 33.0% premium to the company's 90-day volume-weighted average share price for the period ended April 25, 2024. Upon completion of the transaction, the company's common stock will no longer be listed on the New York Stock Exchange, and the company will become a private company. U.S. Silica will continue operating under the U.S. Silica name and brand and will continue to be led by Bryan Shinn and the current executive team. The transaction, which has been unanimously approved by U.S. Silica's Board of Directors, is expected to close in the third quarter of 2024, subject to customary closing conditions, including approval by U.S. Silica stockholders and receipt of regulatory approvals. The transaction is not subject to a financing condition. The definitive agreement includes a 45-day "go-shop" period that will expire at 12:01 AM ET on June 10, 2024, which permits U.S. Silica and its financial advisor to actively initiate, solicit and consider alternative acquisition proposals from third parties. U.S. Silica's Board of Directors will have the right to terminate the agreement to enter into a superior proposal, subject to the terms and conditions of the agreement. There can be no assurance that this process will result in a superior proposal, and U.S. Silica does not intend to disclose developments with respect to the "go-shop" process unless and until it determines such disclosure is appropriate or is otherwise required, subject to the terms and conditions set forth in the agreement.

07:04 EDT Biotricity announces 'high demand' for Biotres Pro - Biotricity announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price. Biotres Pro is expected to raise the average subscription price by over 32%. This will translate to a revenue increase of up to 10% from sales to existing customers over the course of fiscal 2025. Biotres Pro is also capturing the attention of new customers. The initial production run of Biotres Pro has sold out, with customers placing pre-orders for the next run, which is scheduled to ship to customers by end of May.

07:03 EDT AutoNation announces additional $1B share repurchase authorization - AutoNation announced that the board of directors authorized the repurchase of up to an additional $1B of common stock under its share repurchase program and has approximately $1.1B under the program. During the first quarter of 2024 the company made capital expenditures of $94M.

07:03 EDT Bristol Myers announces EMA's CHMP recommended approval of Opdivo - Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo, or nivolumab, in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. The European Commission, or EC, which has the authority to approve medicines for the European Union, will now review the CHMP recommendation. The final EC decision is expected in June 2024. The positive CHMP opinion is based on results from a sub-study of the CheckMate -901 trial which were presented at the European Society of Medical Oncology, or ESMO, Congress 2023. In the sub-study, Opdivo in combination with cisplatin and gemcitabine followed by Opdivo monotherapy demonstrated statistically significant and clinically meaningful improvements in the primary efficacy endpoints of overall survival and progression-free survival as assessed by Blinded Independent Central Review. With a median follow up of approximately 33 months, treatment with Opdivo in combination with cisplatin and gemcitabine reduced the risk of death by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with cisplatin-gemcitabine alone. Patients receiving Opdivo in combination with cisplatin and gemcitabine had their risk of disease progression or death reduced by 28%, with a median PFS of 7.9 months compared to 7.6 months with cisplatin-gemcitabine alone.

07:02 EDT Interactive Strength partially converts senior loan to equity - Interactive Strength had converted $3.0 million of the Company's $8.0 million senior loan to equity and extended the maturity of the remaining loan balance to December 2024. Trent Ward, Co-Founder and CEO of TRNR, said: "We continue to make progress towards financial stability with the reduction of liabilities and the extension of maturity of our senior loan. We expect to be approaching profitability as early as the fourth quarter of this year based on the performance of the CLMBR business that we acquired in February. As part of that transaction, we assumed some of the liabilities of CLMBR, including this senior loan, and we expect that the Company will be able to re-finance the loan as it matures."

06:48 EDT Pfizer announces approval of BEQVE by FDA for adults with hemophilia B - Pfizer announced that the FDA has approved BEQVE, or fidanacogene elaparvovec-dzkt, for the treatment of adults with moderate to severe hemophilia B who currently use factor IX, or FIX, prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var, or AAVRh74var, capsid as detected by an FDA-approved test. BEQVEZ is a one-time treatment that is designed to enable people living with hemophilia B to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that are often administered multiple times a week or multiple times a month. Hemophilia B is a rare genetic bleeding disorder that prevents normal blood clotting because of a deficiency in FIX that causes those with the disease to bleed more frequently and longer than others. With BEQVEZ now approved for use, Pfizer is launching an innovative warranty program based on durability of patient response to treatment. The goal of the warranty is to provide greater certainty to payers, maximize access for eligible patients who receive BEQVEZ, and offer financial protection by insuring against the risk of efficacy failure. BEQVEZ is currently under review with the European Medicines Agency, and the treatment recently received regulatory approval in Canada.

06:43 EDT GrafTech sees FY24 CapEx $35M-$40M - The company said, "We expect demand for graphite electrodes in the near term will remain weak, reflecting persistent challenges in the commercial environment as steel industry production remains constrained by global economic uncertainty. Given these trends, challenging pricing dynamics have persisted in most regions. As a result, we remain selective in the commercial opportunities we choose to pursue. Sales volume in the Q2 is expected to be broadly in line with sales volume for the first quarter of 2024 and we continue to expect a modest year-over-year improvement in sales volume for the full year. We now expect the year-over-year decline in our full year 2024 cash cost of goods sold per MT to exceed our previous guidance of a low-teen percentage point decline compared to 2023. Reflecting the progress we are making on addressing our cost structure, we now anticipate a mid-teen percentage point decline compared to 2023. The significant improvement in our year-over-year costs reflects the strategic actions we are taking to reduce our fixed manufacturing costs, the benefit of additional actions we are taking to reduce our variable costs, including certain raw materials and energy and the anticipated improvement in our sales and production volume levels. In addition, we continue to closely manage our working capital levels and capital expenditures. We continue to anticipate our full-year 2024 capital expenditures will be in the range of $35M-$40M. Longer term, we remain confident that the steel industry's accelerating efforts to decarbonize will lead to increased adoption of the electric arc furnace method of steelmaking, driving long-term demand growth for graphite electrodes. We also anticipate the demand for petroleum needle coke, the key raw material we use to produce graphite electrodes, to accelerate driven by its utilization in producing synthetic graphite for use in lithium-ion batteries for the growing electric vehicle market. We believe that the near-term actions we are taking, supported by an industry-leading position and our sustainable competitive advantages, including our substantial vertical integration into petroleum needle coke via our Seadrift facility, will optimally position GrafTech to benefit from that long-term growth."

06:37 EDT Ault ends marketing process for its subsidiary's four hotels. - Ault Alliance announced that it has ended the marketing process for its four hotels owned and operated by its wholly owned subsidiary, Ault Global Real Estate Equities. As a result, it was determined that the AGREE assets and liabilities previously presented as assets and liabilities held for sale within the Company's balance sheet will no longer meet the held for sale criteria. Assets of $91.0M and liabilities of $70.4M as of December 31, 2023 were reported as assets and liabilities held for sale. In future periods, assets and liabilities of AGREE will be reclassified to assets and liabilities held and used and amounts previously presented in discontinued operations will be reclassified into continuing operations for all periods presented. Milton "Todd" Ault, III, the Company's Executive Chairman, stated, "The timing was not optimal for the sale of our hotel properties which included $16.5M in revenue for FY23 and approximately $91M in assets as of December 31, 2023. Going forward, we have a strong belief in the long-term value of the properties and the real estate sector as a whole and will continue to nurture and operate the assets to the best of our ability."

06:33 EDT Exxon Mobil sees Pioneer Natural merger closing in Q2 - In October 2023, ExxonMobil (XOM) announced an agreement to merge with Pioneer Natural Resources (PXD) in a $59.5B all-stock transaction. The transaction was approved by Pioneer shareholders. The transaction close is anticipated in the second quarter of 2024, pending regulatory approval.

06:17 EDT Chevron reports Q1 worldwide production 12% higher than a year ago - Returned $6B cash to shareholders; eighth straight quarter over $5B. Achieved key project milestones in Kazakhstan, East Mediterranean and U.S.

06:13 EDT Toyota to invest $1.4B in its Princeton facility, brings production of new BEV - Toyota will prepare for assembly of an all-new, three row battery electric SUV in the U.S. as part of a new $1.4B investment in its Princeton facility, affirming Toyota's commitment to reinvesting profits in its U.S. operations and bringing total investment in Toyota Indiana to $8 billion. This also brings the addition of up to 340 new, high-quality jobs with long-term stability. This investment will not only provide plant infrastructure to build the all-new battery electric vehicle, BEV, it will add a new battery pack assembly line using lithium-ion batteries supplied by Toyota Battery Manufacturing North Carolina, a $13.9B facility slated to begin production in 2025. Toyota's Indiana facility is home to more than 7,500 team members who assemble the Toyota Sienna, Highlander, Grand Highlander and the Lexus TX.

05:27 EDT Burning Rock Biotech announces one-for-ten ratio change - Burning Rock Biotech announced that it will change the ratio of its American depositary shares to Class A ordinary shares from one ADS representing one Class A ordinary share to one ADS representing ten Class A ordinary shares. The ADS ratio change is expected to become effective on or about May 15. For Burning Rock's ADS holders, the ADS Ratio Change will have the same effect as a one-for-ten reverse ADS split. There will be no change to the company's Class A ordinary shares. On the effective date, registered holders of the company's ADSs held in certificated form will be required on a mandatory basis to surrender their certificated ADSs to Citibank, the depositary bank, for cancellation and will receive one new ADS in exchange for every ten existing ADSs surrendered. Holders of uncertificated ADSs in the Direct Registration System and The Depository Trust Company will have their ADSs automatically exchanged and need not take any action. The exchange of every ten then-held ADSs for one new ADS will occur automatically at the effective date, with the then-held ADSs being cancelled and new ADSs being issued by the depositary. Burning Rock's ADSs will continue to be traded on the Nasdaq Global Market and London Stock Exchange under the symbol (BNR).

05:20 EDT Silvercorp Metals to acquire Adventus in C$200M transaction - Silvercorp Metals announced that the parties have entered into a definitive arrangement agreement pursuant to which Silvercorp has agreed to acquire all of the issued and outstanding common shares of Adventus by way of a plan of arrangement. Under the terms of the arrangement agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus share at the effective time of the transaction. The exchange ratio implies consideration of C$0.50 per adventus share based on the 20-day volume-weighted average prices, or VWAP, of Silvercorp Shares on the Toronto Stock Exchange on April 25. This represents a premium of 31% based on the 20-day VWAP of Silvercorp on the TSX and Adventus on the TSX Venture Exchange, both as at April 25. The implied equity value of the Transaction is approximately C$200M on a fully-diluted in-the-money basis. At closing, existing Silvercorp and Adventus shareholders will own approximately 81.6% and 18.4%, respectively, of Silvercorp shares outstanding on a fully-diluted in-the-money basis. Concurrent with entering into the arrangement agreement, Silvercorp and Adventus entered into an investment agreement pursuant to which Silvercorp will subscribe for 67,441,217 Adventus Shares at an issue price of C$0.38 per share, or C$25.63M in the aggregate. Upon completion of the Placement, Silvercorp will hold approximately 15% of the total issued and outstanding shares of Adventus. Proceeds from the placement will be used to repay the amounts outstanding under a credit facility with Trafigura Pte in the amount of approximately C$9.9M, which includes penalties payable for the early repayment under the facility, fund the settlement of the outstanding amounts payable pursuant to a convertible loan agreement between Adventus and Altius Resources in the amount of approximately C$9.6M, fund normal course activities at the El Domo project in the amount of approximately C$2.7M, and fund general working capital expenses in the amount of C$3.4M, which expenses are expected to include funding of early development expenditures to advance construction of the El Domo project and fund general and administrative expenses between announcement and closing of the transaction. The funding of the above listed expenses through the placement was a critical factor in Silvercorp determining to proceed with the transaction, as the majority of the expenses must be paid prior to the closing of the Transaction and Adventus does not have sufficient cash on hand to fund these costs. Silvercorp has requested the repayment of the Altius Loan as under the terms of this loan, Altius has the right to increase its royalty on the El Domo project. It is Silvercorp's view that if this royalty right was exercised, it would have a negative impact on the project economics. Silvercorp has also requested the repayment of the Trafigura Facility, which matures on June 30, prior to the closing of the transaction. The remaining use of proceeds as set out above, are being directed towards general, administrative, project maintenance and project advancement expenditures, which expenditures will allow Adventus to keep the projects in good standing and continue or commence project development activities. Silvercorp views the funding of these expenses to be essential in terms of maintaining the goodwill of the company within the local community and the various levels of government. The completion of the placement has been conditionally approved by the TSXV and remains subject to final acceptance by the TSXV on behalf of Adventus for the listing of the Adventus shares to be issued to Silvercorp. The Adventus shares to be issued to Silvercorp will be subject to a statutory four-month hold period under applicable securities laws. Completion of the placement and the repayment of indebtedness does not provide a guarantee that the transaction will be completed. Under the terms of the transaction, Silvercorp will acquire all the issued and outstanding Adventus Shares and Adventus shareholders will receive 0.1015 Silvercorp Shares for each existing Adventus Share held. All outstanding Adventus stock options and warrants will become exercisable for Silvercorp Shares, with the number of Silvercorp Shares issuable on exercise and the exercise price adjusted in accordance with the Exchange Ratio. All outstanding Adventus restricted share units will immediately vest upon closing of the transaction and be settled in cash, funded by Silvercorp through Adventus. The transaction will be carried out by way of a court-approved arrangement under the Canada Business Corporations Act and a resolution to approve the transaction will be submitted to Adventus shareholders and holders of Adventus stock options and restricted share units at a special meeting of securityholders expected to be held on or about June 28. The transaction will require approval by 66 2/3% of the votes cast by Adventus shareholders and holders of options and restricted share units voting as a single class, and a simple majority that excludes those not entitled to vote in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. Each of the directors and senior officers of Adventus, Ross Beaty and Wheaton Precious Metals Corp., representing in aggregate approximately 23% of the issued and outstanding Adventus Shares, have entered into voting support agreements with Silvercorp and have agreed to vote in favor of the transaction at the special meeting in accordance with those agreements. In addition, Salazar has entered into an agreement with Silvercorp whereby they have indicated they will support the transaction. In addition to Adventus securityholder and court approval, the transaction is also subject to the satisfaction of certain other closing conditions customary for a transaction of this nature. The transaction has been conditionally approved by the TSXV but remains subject to final approval of the TSXV on behalf of Adventus, and approval of the TSX and NYSE American on behalf of Silvercorp, including the acceptance for listing of the Silvercorp shares to be issued in connection with the transaction. The transaction is expected to be completed in the third quarter of 2024. The arrangement agreement includes representations, warranties, covenants, indemnities, termination rights and other provisions customary for a transaction of this nature. In particular, the arrangement agreement provides for customary deal protections, including a non-solicitation covenant on the part of Adventus and a right for Silvercorp to match any superior proposal. The arrangement agreement includes a termination fee of C$10M, payable by Adventus, under certain circumstances. BMO Capital Markets is acting as financial advisor to Silvercorp. McCarthy Tetrault and FBPH Abogados are acting as Silvercorp's Canadian and Ecuadorian legal advisors, respectively. Cormark Securities is acting as financial advisor to Adventus. Bennett Jones and AVL Abogados are acting as Adventus' Canadian and Ecuadorian legal advisors, respectively.